The post discusses a successful hair loss treatment involving a hair transplant, finasteride, and minoxidil. The user underwent a 2000 graft hair transplant at the hairline in a clinic in Sweden.
Hair loss treatment involves gland treatment with iodine, liver extract, wild American ginseng, and black cohosh, along with crude oil scalp massage. The approach aims to stimulate hormones and improve blood circulation to promote hair growth.
Hair loss treatments are difficult because hair follicles react differently to hormones and have varying growth cycles. Treatments mentioned include Minoxidil, finasteride, and RU58841.
The user experienced significant hair improvement after 4 months of using 1.25mg finasteride daily and 5% Minoxidil foam. They reported no side effects and no noticeable shedding phase.
PP405 significantly improves hair density, outperforming finasteride, with 31% of users seeing over 20% improvement in four weeks. Concerns exist about its availability, cost, and long-term effects.
The user shared their positive 5-month results using finasteride, minoxidil, derma rolling, and supplements like biotin, zinc, iron, and vitamin C. They provided before and after photos and mentioned applying minoxidil even when derma rolling.
A 32-year-old is seeing positive hair regrowth after nearly three months using finasteride, oral and liquid minoxidil, and microneedling, and plans to add RU58841. They are considering switching to dutasteride and possibly a hair transplant in the future.
The conversation is about someone's progress with hair loss treatment using topical finasteride, minoxidil, and weekly manual microneedling. A reply indicates that they have made noticeable progress.
A user is upset about hair loss due to seborrheic dermatitis and DUPA, which prevents a hair transplant. They mention using jojoba oil and discuss treatments like Minoxidil, finasteride, and RU58841.
The conversation discusses the delay in bringing FAK inhibitors and Stanford's hydrogel to market for hair transplants, with a preference for FAK inhibitors over Verteporfin due to their superior potential in preventing scarring. The user expresses frustration over the slow progress and hopes for faster development by companies like FAKnostics.